Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches

Executive Summary

Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.


Related Content

Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Novartis Finds All-Important Head Of Oncology Business At Pfizer
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Response Rates Rule In CGRP Inhibitor Migraine Studies
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Novartis Rejiggers Pharma To Favor Oncology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts